Cue Biopharma Inc
CUE
Get informed when a big investor buys or sells
+ FollowMarket Cap$89.88M
Close$
$-0.76
102.4% downside
Current Fair Value
102.4% downsideOvervalued by 102.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $89.88 Million |
|---|---|
| Enterprise Value | $75.56 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.4 |
| Beta | 2.47 |
| Outstanding Shares | 6,340,844 |
Return
| Return on Equity | -7104.24% |
|---|---|
| Return on Assets | -534.43% |
| Return on Invested Capital | -1043.34% |
Valuation & Multiples
| P/E Ratio | -1.27 |
|---|---|
| PEG | -0.07 |
| Price to Sales | 6.22 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.01 |
| Enterprise Value to EBIT | -0.76 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 1.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-3.30
Average shareholder expectationRevenue Estimate
$2.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
$-1.69
Average shareholder expectationRevenue Estimate
$3.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 34,900▲ Infinity% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.33%▼ 12.50% |
|---|---|
| Total Invested | $3.53M▼ 28.69% |
| Investors Holding | 14▼ 40.00% |
ESG Score
No data
About Cue Biopharma Inc
CEO: Daniel Passeri